Product Description
Mechanisms of Action: V1 Agonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/14/2024 |
PubMed |
Recurrent Auricular Keloid After Childbirth in a Patient With von Willebrand Disease. |
|
05/02/2024 |
PubMed |
Kidney collecting-duct-derived vasopressin is not essential for appropriate concentration or dilution of urine. |
|
04/24/2024 |
PubMed |
A cAMP-biosensor-based assay for measuring plasma arginine-vasopressin levels. |